Skip to main content
. Author manuscript; available in PMC: 2017 Aug 10.
Published in final edited form as: Cell Host Microbe. 2016 Jul 14;20(2):189–201. doi: 10.1016/j.chom.2016.06.007

Figure 3. Antiviral activity of divergent Tetherin/TM-CC-GPI proteins.

Figure 3

(A) Tetherin/TM-CC-GPI Protein sequences from human (GenBank: NP_004326.1), mouse (GenBank: NP_932763.1), opossum (GenBank: XP_007489270.1 and XP_007489271.1), Tasmanian devil (GenBank: XP_012399618.1), turtle (GenBank: XP_008169758.1, XP_005279001.1 and XP_005279003.1), turkey (inferred from GenBank: XP_010723307.1), falcon (inferred from GenBank: XP_005444407.1 and Gnomon prediction: 2189215010.p), alligator (GenBank: XP_006017475.1 and XP_006017476.1), coelacanth (Gnomon prediction: 16424589.p), elephant shark (GenBank: XP_007897024.1) Tetherin/TM-CC-GPI proteins (see also Supplemental Information). The TM, CC domains and GPI anchor are indicated. Conserved residues are highlighted and predicted omega sites (GPI modification) are indicated in grey.

(B) Infectious virion yield measured using HeLa TZM-bl indicator cells following transfection of Vpu-deficient HIV-1 proviral plasmids along with plasmids expressing Tetherin/TM-CC-GPI proteins. (RLU= relative light units, Mean ± SD, n=3).

(C) Western blot analyses (anti-CA) of cell lysates and virions corresponding to (B). Numbers at the bottom represent virion CA protein levels relative to those obtained in the absence of an inhibitor.

See also Figure S3.